It is believed that interstitial fluid pressure and solid stress are major obstacles preventing efficient delivery of macromolecules into tumor tissue, as well as stroma and an immunosuppressive tumor microenvironment.
One promising solution is to modulate the tumor microenvironment with biophysics using a combination of gas microspheres and ultrasound to introduce new cellular-level biophysical modes of action to work in concert with the molecular mechanism of action of a selected active drug. This effect can be limited to the target by aiming the ultrasound transducer and beam only at the tumor area to ensure total tumor coverage as well as treatment to the immediate periphery of tissue.
Vesselon’s Imagent® lipid microsphere can be co-formulated with any biologic macromolecules or with lipid nanoparticles and viral vectors to augment the biodistribution of these important drugs, without having to modify those drugs in any way.
Mr. Larsen co-founded Vesselon in 2012 and brings over thirty years of executive management in the healthcare industry. Mr. Larsen was a senior executive with FUJIFILM Medical Systems, where he was largely responsible for building the company’s first healthcare software division from the ground up. Mr. Larsen recruited the original senior architects and was instrumental in the development, marketing, commercial release and field support of Fuji's Synapse® Picture Archive and Communication System (PACS). Currently the Synapse VNA is one of the industry’s leading image-enablement solutions, managing 40 billion objects for 1,500 facilities across six continents. In a move to Silicon Valley in 1988, Mr. Larsen served in several senior roles at Acuson Corporation leading the roll out of Color Doppler technology to the industry and culminating as Vice President of New Market Development. Acuson was one of the leading ultrasound technology companies that was later acquired by Siemens. Mr. Larsen holds a B.S. in Molecular Biophysics and Biochemistry from Yale University.
Llew Keltner, M.D., Ph.D., has a 40-year career in biopharma drug and business development. He is Chief Executive Officer of EPISTAT, an international healthcare strategy company he founded in 1972. Dr. Keltner was CEO of AgonOx, developing OX40 agonists for cancer therapy; President of Novici Biotech, a privately-held gene and protein optimization firm; CEO of Light Sciences Oncology, developing a late stage, light-activated therapy for solid tumors and Dr. Keltner was CEO of Metastat, a biotech company focused on cancer metastasis.
Dr. Keltner holds positions on the boards of Curetech, Infostat, BioQ Pharma, Oregon Life Sciences, Surgeon Training International, OncoSCAR, and Goodwell Technologies. Dr. Keltner is Assoc Professor at Case Western Reserve School of Medicine, and a Guest Lecturer and Director in the Bioethics Program at Columbia University School of Medicine. He is currently a member of ASCO, AACR, AMA,, Intl Assoc of Tumor Marker Oncology, Amer Assoc of Clinical Chemistry, and Drug Information Assoc. Dr. Keltner received an M.S. in Epidemiology and Biostatistics, a Ph.D. in Biomedical Informatics and an M.D. from Case Western Reserve in Cleveland, Ohio.
Joseph Truitt currently serves as the CEO and Board member of iECURE Inc. Mr. Truitt previously was CEO of BioSpecifics Technologies Corp., which was recently acquired by Endo Pharmaceuticals for $658 million. Prior to BioSpecifics, Mr. Truitt was CEO of Achillion Pharmaceuticals, which he joined in 2009 and held positions of increasing responsibility throughout his tenure, executing a strategic transaction with Alexion for $1.2 billion. Mr. Truitt is Chairman of the board at Larimar Therapeutics and serves on the board of Code BioTherapeutics. Mr. Truitt served as a Captain in the United States Marine Corps. He holds an MBA from Saint Joseph’s University and a BS from LaSalle University. Mr. Truitt works with Vesselon in the capacity of Business Advisor, Strategic Alliances.
During his 30-year career in pharmaceutical research and development, Lawrence T. Friedhoff, MD, PhD, FACP developed and brought two chemical compounds through regulatory approvals around the world. These new drugs are market blockbusters, each used by millions of patients and each generating well over $1 billion annual revenue worldwide. Dr. Friedhoff has held management positions at multi-national corporations, developing novel drug compounds, small publicly-traded companies manufacturing generic drugs, start-up ventures, and academic-based research teams writing business plans to obtain venture capital. As an R&D head, he has managed post-FDA-approval activities including collecting and analyzing adverse-event information from consumers, fielding inquiries from patients and healthcare providers, and marketing-related scientific studies.
As head of the client success team at Endpoints News, Kari oversees campaign delivery and strategy for all advertising and client-directed webinars. She brings nearly 20 years of diverse experience across strategic communications, content development and operational leadership.